Tumor Markers for Efficacy of Dual-Target Therapy in HER2+ Breast Cancer

Authors
Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2025
This is a prospective, randomized study to compare the efficacy of TP (Taxane plus Carboplatin) chemotherapy combined with dual-HER2 blockade (trastuzumab and pertuzumab) versus TP chemotherapy plus single-HER2 blockade (trastuzumab) in patients with HER2-positive breast cancer. The study aims to evaluate treatment response and the clinical value of serum tumor markers (CEA, CA125, and CA153) in assessing therapeutic efficacy.
Epistemonikos ID: 7ddeb0d1451efb946004d8eefe42ef9d0a91672d
First added on: Aug 12, 2025